BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

AZD6244 (ARRY 142886) is a potent and selective mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor currently in early clinical trials. We examined the activity of AZD6244 in a panel of non-small cell lung cancer and a panel of cell lines representing many cancer types using in vitro growth assays. AZD6244 induced G(0)-G(1) cell cycle arrest in sensitive cell lines that primarily included cells containing the BRAF V600E mutation. In these cells, G(0)-G(1) arrest is accompanied by the up-regulation of the cell cycle inhibitors p21(WAF1) and p27(Kip1) and down-regulation of cyclin D1. In the majority of cell lines tested, including those with K-ras or non-V600E BRAF mutations, AZD6244 induced the accumulation of phospho-MEK, an effect not observed in the most sensitive BRAF V600E-containing cells. Accumulation of phospho-MEK in non-V600E-containing cell lines is due to abrogation of negative feedback pathways. BRAF V600E disrupts negative feedback signaling, which results in enhanced baseline phospho-MEK expression. Exogenous expression of BRAF V600E disrupts feedback inhibition but does not sensitize cells to AZD6244. Specific suppression of endogenous BRAF V600E does not confer resistance to AZD6244 but enhances sensitivity to AZD6244. Thus, our findings show that BRAF V600E marks cells with an in vitro requirement for MAPK signaling to support proliferation. These cells are exquisitely sensitive to AZD6244 (IC(50), <100 nmol/L), have high baseline levels of phospho-MEK, and lack feedback inhibition between ERK and Raf. These data suggest an approach to identifying cells that may be sensitive to AZD6244 and other MEK inhibitors.

[1]  J. Groffen,et al.  Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. , 1986, Nucleic acids research.

[2]  Jonathan D. Licht,et al.  Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation* , 2001, The Journal of Biological Chemistry.

[3]  M. Kohno,et al.  ERK pathway positively regulates the expression of Sprouty genes. , 2001, Biochemical and biophysical research communications.

[4]  J. Brognard,et al.  Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants , 2002, Cell Death and Differentiation.

[5]  Jing Chen,et al.  Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[7]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[8]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[9]  M. Santoro,et al.  BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma , 2006, Clinical Cancer Research.

[10]  J. Sebolt-Leopold,et al.  Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro* , 2003, Journal of Biological Chemistry.

[11]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[12]  E. Fauman,et al.  Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352 , 2002, Molecular and Cellular Biology.

[13]  A. Porter,et al.  Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis , 1998, Oncogene.

[14]  N. Munshi,et al.  Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. , 2007, Blood.

[15]  M. Reth,et al.  Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.

[16]  H. Huynh,et al.  Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[17]  G. Kéri,et al.  Signaling through RAS-RAF-MEK-ERK: from basics to bedside. , 2007, Current medicinal chemistry.

[18]  J. Sandoval,et al.  Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. , 2006, Journal of pediatric surgery.

[19]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[20]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[21]  Steven P Gygi,et al.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Lyssikatos,et al.  Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.

[23]  David P. Davis,et al.  Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.

[24]  E. Nishida,et al.  Identification of the Anti-proliferative Protein Tob as a MAPK Substrate* , 2002, The Journal of Biological Chemistry.

[25]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[26]  R. Huddart,et al.  Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. , 2005, Neoplasia.

[27]  G. Troncone,et al.  Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). , 2006, European journal of endocrinology.

[28]  Walter Kolch,et al.  Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.

[29]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[30]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[31]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[32]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[33]  P. Bastiaens,et al.  Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.

[34]  G. Pavlath,et al.  Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. , 1998, Molecular biology of the cell.

[35]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[36]  A. Adjei,et al.  K-ras as a target for cancer therapy. , 2005, Biochimica et biophysica acta.

[37]  Alan P. Brown,et al.  Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration , 2007, Cancer Chemotherapy and Pharmacology.

[38]  W. W. Nichols,et al.  Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene , 1990, Molecular and cellular biology.

[39]  M. Schott.  Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 , 2008 .

[40]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[41]  B. Weber,et al.  SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.

[42]  G. Guy,et al.  Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf* , 2002, The Journal of Biological Chemistry.

[43]  D. Kerr,et al.  Ras as a target in cancer therapy. , 2002, Critical reviews in oncology/hematology.

[44]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.